A trial of antilymphocyte globulin in the treatment of chronic progressive multiple sclerosis

Walker, Joanne E.; Hoehn, Margaret M.; Kashiwagi, Noboru

doi:10.1016/0022-510x(76)90179-9

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The B cell‐depleting therapy is divided into two categories; polyclonal and monoclonal antibody therapies. Polyclonal antibody therapies inhibit cell‐mediated immune reactions by causing general immunosuppression, albeit not commonly used in MS due to high toxicity (Walker, Hoehn, & Kashiwagi, ). On the other hand, numerous monoclonal antibodies including Natalizumab, Alemtuzumab and Daclizumab have proven effective in early RRMS(Nguyen, Gresle, Marshall, Butzkueven, & Field, ).…”

Section: Animal Models and Treatment Optionsmentioning

confidence: 99%

Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis

Tiwari

Lapierre

Ojha

et al. 2018

J of Neuroscience Research

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated demyelinating disorder of unknown etiology. Both genetic-susceptibility and environment exposures, including vitamin D deficiency, Epstein-Barr viral and Herpesvirus (HHV-6) infections are strongly implicated in the activation of T cells and MS-pathogenesis. Despite precise knowledge of how these factors could be operating alone or in combination to facilitate and aggravate the disease progression, it is clear that prolonged induction of inflammatory molecules and recruitment of other immune cells by the activated T cells results in demyelination and axonal damage. It is imperative to understand the risk factors associated with MS progression and how these factors contribute to disease pathology. Understanding of the underlying mechanisms of what factors triggers activation of T cells to attack myelin antigen are important to strategize therapeutics and therapies against MS. Current review provides a detailed literature to understand the role of both pathogenic and non-pathogenic factors on the impact of MS.

show abstract

Section: Animal Models and Treatment Optionsmentioning

confidence: 99%

Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis

Tiwari

Lapierre

Ojha

et al. 2018

J of Neuroscience Research

View full text Add to dashboard Cite

show abstract

“…Uncontrolled studies of the therapeutic value of ALS have been carried out in patients with various diseases, including multiple sclerosis (Lance et al 1975, Walker et al 1976), myasthenia gravis (Pirofsky et al 1979), and immunologicaily-mediated renal diseases (Pirofsky et al 1969). The results of these studies are difficult to interpret.…”

Section: Other Diseasesmentioning

confidence: 99%

Clinical Experience with Antilymphocyte Serum

Heyworth

1982

Immunological Reviews

View full text Add to dashboard Cite

Many different antilymphocytic antisera have been used clinically, and the properties of any particular type of ALS are not necessarily identical to those of any other type. Nevertheless, it is possible to draw certain general conclusions about the effects of ALS in human subjects. ALS administration has often been shown to reduce the number of circulating E-rosette-positive lymphocytes, although the precise mechanisms by which this reduction occurs are not known. Using a combined technique of E-rosette formation and immunofluorescence, heterologous immunoglobulin has been demonstrated on T and non-T lymphocytes from patients receiving non-selective ALS. Fifteen years' experience has failed to provide convincing support for the view that ALS (including immunoglobulin prepared from the whole antiserum) prolongs human renal allograft survival. It is not yet known whether ALS is a useful immunosuppressive agent in cardiac transplantation. One observation of possible clinical interest is that bone marrow regeneration has occurred in a number of patients with aplastic anemia who have been treated with ALS. No satisfactory method has been developed for monitoring the dose of ALS in human subjects. Appropriate studies may determine whether monoclonal antilymphocytic antibodies are clinically useful, for example in prolonging the survival of transplanted organs, in preventing or treating graft-versus-host disease, or in treating lymphoma, leukemia, or aplastic anemia.

show abstract

“…Following the demonstration of antithymocyte globulin's (ATG) effectiveness in suppressing established experimental allergic encephalomyelitis (Brendeletal., 1969;Landet al, 1969;, it was used to treat the acute relapsing form (Brendel, 1971;Pirofski et al, 1971;Seland et al, 1974;Trouillas et al, 1970) and the chronic progressive form (Walker et al, 1976) of multiple sclerosis (M.S.). The encouraging results of preliminary studies have led to further investigation of immunosuppression in the treatment of M.S.…”

mentioning

confidence: 99%

Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

1978

Can. j. neurol. sci.

View full text Add to dashboard Cite

SUMMARY:Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.

show abstract

A trial of antilymphocyte globulin in the treatment of chronic progressive multiple sclerosis

Cited by 8 publications

References 11 publications

Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis

Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis

Clinical Experience with Antilymphocyte Serum

Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

Contact Info

Product

Resources

About